Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology
Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-generation immuno-oncology therapies from Harpoon Therapeutics, Inc. at the upcoming European Congress on Biotechnology (ECB) on Tuesday, July 3 from 10:30 to 11:00 a.m. CEST in Geneva, Switzerland.
Dr. Baeuerle co-founded Harpoon Therapeutics in 2015 with a vision to build an innovative class of T cell engaging therapeutics optimized to achieve superior efficacy in penetrating solid tumors as an “off-the-shelf” T cell therapy. T cell engagers are unique in their ability to redirect lysis independently of T cell receptor (TCR) specificity and recognition of human leukocyte antigen (HLA) / peptide antigen – the loss of which being a frequent mechanism by which cancer cells escape T cell recognition.
His presentation, entitled “TriTAC™: A novel therapy to treat cancer,” will focus on compelling preclinical data from Harpoon’s TriTAC technology that underscores its potential to overcome the limitations and liabilities of existing T cell-engaging antibody therapies.
Supported by investments led by MPM and the UBS Oncology Impact Fund (OIF) managed by MPM, Harpoon Therapeutics anticipates launching two TriTAC programs in the clinic within the year. The company’s lead candidate, HPN424, targets prostate-specific membrane antigen (PSMA) and will be investigated for use in the treatment of patients with prostate cancer. Its second product candidate, HPN536, targets mesothelin and will be investigated for use in the treatment of patients with a variety of solid tumors.
Dr. Baeuerle, an immunologist by training, is known for his role in the development of the first bispecific T cell engager (BiTE) for hematologic malignancies, Blincyto® (blinatumomab), which was approved by the U.S. Food and Drug Administration (FDA) in less than 3 months in 2014 -- the fastest FDA approval for a cancer drug ever. In 2015, he joined MPM and since then has co-founded six companies with MPM and the UBS OIF in his continued pursuit of novel immunotherapies for cancer.
The ECB is the leading congress for academic and industrial biotechnologists in Europe and the flagship biennial event of the European Federation of Biotechnology. For complete details, please visit www.ecb2018.com.
About Harpoon Therapeutics
Harpoon Therapeutics is an
immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in
the development of T-cell engaging therapies, and MPM Capital. The
company is focused on the discovery and development of novel T cell
engaging biologics for the treatment of cancer and other diseases.
Harpoon Therapeutics created a novel antibody-based drug discovery
platform called TriTAC™ (tri-specific T cell activating construct) to
unleash the targeted cell-killing properties of a patient’s own immune
system through T cell activation. This approach has been optimized to
penetrate tissues and extend serum exposure, and has the potential to
address a broad range of cancers, including solid tumors, and
immunologic diseases. HPN424, a prostate-specific membrane antigen
(PSMA)-targeting TriTAC™ biologic, is in development for the treatment
of prostate cancer and is expected to enter a clinical trial in 2018.
For more information, please visit www.harpoontx.com.
About MPM Capital
MPM Capital is a venture firm founding and
investing in early-stage life sciences companies that seek to cure major
diseases by translating scientific innovations into positive clinical
outcomes. MPM’s portfolio of companies aims to revolutionize the face of
medicine across multiple areas including cancer, neuroscience, metabolic
disorders and regenerative medicine. With its experienced and dedicated
investment team, executive partners and entrepreneurs, and its medical
and scientific advisory board, MPM is powering novel medical
breakthroughs that transform patients’ lives. MPM is currently investing
from its BV2014 and BV2018 funds. It also invests from the UBS Oncology
Impact Fund managed by MPM -- the first-of-its-kind, oncology-only
social impact fund that donates a portion of its profits and royalties
to cancer research and cancer care. For further information, please
visit www.mpmcapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180626005732/en/
Contact information
For MPM Capital
Liz Doherty, +1 617-425-9275
ldoherty@mpmcapital.com
or
For
MPM Capital/UBS Oncology Impact Fund
Kathy Vincent, +1 310-403-8951
kathy@kathyvincent.com
or
For
Harpoon Therapeutics
Kinkead Communications, Inc.
Susan
Kinkead, +1 415-509-3610
susan@kinkeadcomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM9.7.2025 04:30:00 EEST | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has obtained “Halal Certificate (Certification Number: 355-TSRI/24)” for its functional food ingredient, KANEKA UBIQUINOLTM (active form of coenzyme Q10) powder, under the assessment of Shariah Research Institute of Takushoku University, and issued by JAPAN MUSLIM ASSOCIATION, a religious corporation, on May 28. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708279133/en/ Halal certificate Halal certification is a system in which relevant organizations verify that products or services do not contain ingredients prohibited under Shariah (Islamic law) and certify their compliance with Shariah. We actively pursue the acquisition of various certifications to ensure the safety and security of our raw materials, and we are pleased to announce that we have obtained a Halal Certificate for KANEKA UBIQUINOLTM. Currently, the Muslim populati
SiPearl: Final closing of €130m Series A with Cathay Venture (Taiwan), EIC Fund and France 20308.7.2025 18:25:00 EEST | Press release
SiPearl, the company building European high-performance energy-efficient processors for supercomputing and AI has achieved the definitive closing of its €130m Series A with a third tranche of €32m. Seed funded by the European Union, SiPearl was launched in January 2020 under the auspices of the European Processor Initiative consortium which aims to foster the return of high-performance energy-efficient processor technologies in Europe. Since then, the company has fulfilled its mission by building a world-class processor team of 200 employees in France, Spain, and Italy, set up its own sovereign infrastructure with data centres in France equipped with servers and emulators dedicated to semiconductor design. SiPearl has completed the conception of the most complex processor ever designed in Europe, Rhea1. With 80 Arm Neoverse V1 cores, Rhea1 is composed of more than 61bn transistors. Several weeks ago, Rhea1 taped-out and was handed off to the world’s leading foundry, TSMC in Taïwan, for
LambdaTest Unveils Smart Branching and Baseline Management to Modernize Visual Testing Workflows8.7.2025 18:00:00 EEST | Press release
LambdaTest, a GenAI-powered quality engineering platform, has announced the release of SmartUI’sSmart Branching and Baseline Management, a major leap forward in visual testing. This update eliminates long-standing bottlenecks caused by outdated baseline strategies and introduces an intelligent, streamlined way for development teams to manage visual testing across complex Git workflows. Modern development teams utilise feature branches, release versions, and hotfix workflows; however, most visual testing tools still rely on comparisons against the main branch, resulting in irrelevant failures and time-consuming approvals. LambdaTest’s SmartUI changes that with features purpose-built for today’s branching strategies. Smart Branch Comparison ensures visual tests are run against the correct baseline, comparing within the same feature branch instead of defaulting to the main. Flexible Merging Options automatically create and approve merged visual states, eliminating the need for manual appr
Connectivity as Versatile as the Aircraft, Starlink High-Speed Internet Now Available for Cessna Caravan8.7.2025 17:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Caravan following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514119/en/ Textron Aviation announced an additional high-speed internet connectivity solution for the Cessna Citation Caravan following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. (Photo: Textron Aviation) “The Cessna Caravan is so versatile,
Rigaku Announces STAvesta, a Thermal Analyzer Tailor-made for Next-generation Material Development8.7.2025 17:00:00 EEST | Press release
Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched worldwide sales of STAvesta, a thermal analyzer that simultaneously measures a sample’s weight and change in calorific value during heating. STAvesta responds to needs in a wide array of fields where thermal analysis is required. It is expected to find use in a wide variety of material-analysis applications for the development of advanced features and complex materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708207135/en/ STAvesta FlatBlank, a Revolutionary Auto-adjustment Feature, Dramatically Reduces Workload In conventional thermal analysis, baseline adjustment must be performed by hand before measurement can begin. This process can be time-consuming and frustrating, particularly for novice users. Rigaku’s newly developed FlatBlank, a baseline auto-adjustment f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom